

March 24, 2021
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President & Chief Executive Officer
(Securities Code: 4582)

Notice of Appointments to the Board of Directors and the Audit & Supervisory Board, and Appointments of Corporate Officers

TOKYO, Japan, March 24, 2021 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo) today announced appointments to its Board of Directors and Audit & Supervisory Board (including appointment of a member and a substitute member of the Audit & Supervisory Board) made by resolution of shareholders approved at the 16th Ordinary General Meeting of Shareholders, and Representative Director and Corporate Officer appointments approved by the Company's Board of Directors at a board meeting convened following the close of the shareholders meeting. The appointments are as follows:

1. Members of the Board of Directors

Name	Title
Fuminori Yoshida	Representative Director
Shigeo Kimura	Director
Shigetoshi Matsumoto	Outside Director
Bruce David Cheson	Outside Director
Eiji Ebinuma (newly appointed)	Outside Director

2. Member of the Audit & Supervisory Board

Name	Title
Yasuhiro Tamou (newly appointed)	Outside Auditor

3. Substitute Member of the Audit & Supervisory Board

Name	Title
Takashi Watanabe	Substitute Member of the Audit & Supervisory Board

4. Corporate Officers

Name	Title
Fuminori Yoshida	Corporate Officer, President and Chief Executive Officer
Shigeo Kimura	Corporate Officer and Senior Managing Officer
Takaaki Fukushima	Corporate Officer and Chief Financial Officer
Masayuki Aboshi	Corporate Officer and Head of Research & Development Division

Yoshiharu Torikai	Corporate Officer and Head of Regulatory Affairs & Quality Assurance Division
Kozo Yoshida	Corporate Officer and Head of Sales Division

[Contact]

Investor Relations

Tel: +81(0)3 5472 1125